![Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study | BMC Psychiatry Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study | BMC Psychiatry](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12888-021-03538-y/MediaObjects/12888_2021_3538_Fig3_HTML.png)
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study | BMC Psychiatry
![SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder](https://d1l0gza1nowsqe.cloudfront.net/wp-content/uploads/sites/4/2022/05/Spravato6001PPS0_620.jpg)
SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder
![Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study | Neuropsychopharmacology Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study | Neuropsychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41386-023-01577-5/MediaObjects/41386_2023_1577_Fig1_HTML.png)
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study | Neuropsychopharmacology
![Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/ajp.2019.176.issue-6/asset/16c05576-8b16-0557-58b1-c0557658b16c/ajp.2019.176.issue-6.cover.jpg)
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry
Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
![Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study | BMC Psychiatry Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study | BMC Psychiatry](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12888-021-03538-y/MediaObjects/12888_2021_3538_Fig2_HTML.png)